Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for ...

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

The Food and Drug Administration (FDA) has granted Fast Track designation to PBGENE-HBV, an investigational gene editing therapy for adults with chronic hepatitis B.